On April 28, 2026, the Acting Attorney General of the United States issued an unprecedented order moving marijuana from Schedule I to Schedule III under the Controlled Substances Act.
The decision took effect immediately, without the public comment, congressional approval, or scientific hearing usually required under federal law. This sudden reclassification has sparked multiple legal challenges, now headed to the United States Court of Appeals for the District of Columbia Circuit, a court known for handling high-profile cases involving federal agencies.
Background On Marijuana Rescheduling
Under the Controlled Substances Act, drugs are classified into schedules based on their medical use, potential for abuse, and safety profile. Previously, marijuana was in Schedule I the most restrictive category, alongside substances such as heroin indicating high abuse potential and no accepted medical use.
By moving marijuana to Schedule III, the federal government places it in the same category as drugs like ketamine and certain anabolic steroids. While this change may benefit state-licensed dispensaries, critics argue it bypasses essential scientific and safety evaluations.
The rescheduling also removes the burdensome Section 280E tax restriction for marijuana businesses, which previously prevented them from deducting standard business expenses.
Overnight, dispensaries potentially avoided hundreds of millions in taxes, raising concerns about fairness for pharmaceutical companies that followed rigorous federal protocols.
MMJ International Holdings’ Challenge
One of the companies challenging the rescheduling is MMJ International Holdings, a biopharmaceutical firm that has invested nearly a decade and more than $10 million developing FDA-compliant cannabinoid therapies for serious neurological conditions such as Huntington’s disease and multiple sclerosis.
Unlike state dispensaries, MMJ adhered strictly to federal protocols, including clinical trials, Orphan Drug designation, DEA registrations, and FDA Investigational New Drug applications.
Duane Boise, CEO of MMJ International, emphasized, “Companies following FDA rules should not be disadvantaged while others bypass the process. Our mission is to demonstrate that cannabinoid medicine works when developed according to science.”
Legal Grounds For The Challenge
MMJ’s lawsuit argues that the government’s April 28 order exceeded statutory and constitutional authority. Key points include:
- Procedural violations: The rescheduling ignored required public hearings and scientific review.
- Patient safety risks: Marijuana products classified as Schedule III have not undergone FDA-approved studies, leading to unregulated dosing, unknown drug interactions, and safety gaps for patients.
- Unconstitutional agency action: DOJ previously acknowledged that administrative judges used for DEA drug scheduling may be unconstitutional.
- Unfair advantage: State dispensaries now gain expedited DEA registration while compliant pharmaceutical developers wait years for approval.
The D.C. Circuit’s decision may establish precedent for federal agency authority and influence how pharmaceutical-grade cannabis is regulated.
Patient Safety Implications
The rescheduling has immediate implications for patient care. While state dispensaries sell products with THC content ranging from 5% to 95%, none have FDA-approved dosing guidelines, package inserts, or standardized safety protocols.
Patients on multiple medications such as blood thinners, diabetes drugs, or statins face unknown risks. MMJ’s petition highlights documented health risks, including psychosis, impaired brain development in adolescents, respiratory damage, cardiovascular complications, and addiction potential.
Federal oversight without scientific validation could jeopardize safe patient care.
Broader Implications For The Pharmaceutical Industry
Beyond marijuana, this case could affect every company that invests in FDA compliance. If the court upholds the rescheduling order, it could incentivize businesses to bypass scientific protocols to reach the market faster.
Conversely, a ruling in favor of MMJ could reinforce the importance of rigorous testing and federal approval for patient safety and equitable market competition.
Timeline Of Key Events
- April 28, 2026: Rescheduling order signed; marijuana moved to Schedule III.
- May 22, 2026: Federal judge dismisses first legal challenge to CMS hemp reimbursement program on procedural grounds.
- May 28, 2026: MMJ files direct challenge to the rescheduling order with the D.C. Circuit.
- June 4-5, 2026: Parallel challenges consolidated; emergency motions filed.
- June 29, 2026: DEA scheduled to begin expedited rescheduling hearing, which may be stayed pending judicial review.
Why This Matters To Patients And Businesses
The litigation has implications for patients, pharmaceutical companies, and the regulatory system. Patients could be exposed to unregulated products with unknown interactions.
Companies that invest in FDA-approved cannabinoid therapies risk losing competitive equity. Finally, the case tests the limits of federal agency authority and may clarify the legal requirements for rescheduling controlled substances.
Looking Ahead
The D.C. Circuit’s ruling will be closely watched. An emergency motion could temporarily halt the DEA’s June 29 hearing, potentially freezing the rescheduling process until the court issues a decision.
The outcome will shape how cannabinoid therapies are regulated, how businesses navigate compliance, and how patient safety is ensured in this rapidly evolving industry.
